
To: All IEHP DualChoice PCPs
From: IEHP Pharmaceutical Services
Date: April 11, 2023
Subject: **Choice90Rx Optimization Program**

Inland Empire Health Plan (IEHP) would like to notify all DualChoice PCPs of the new **Choice 90Rx Optimization Program**.

This program is focused on increasing medication adherence by encouraging prescribers to extend days' supply to 90 days for Member prescriptions. The goal of the program is to increase Member adherence and thus, improve health outcomes.

Beginning April 2023, DualChoice PCPs may receive fax communications from MedImpact requesting Providers to **switch their Member(s) to a 90-day supply for diabetes, cholesterol, and blood pressure drugs** for the following eligible drug classes:

- ✓ Statins
- ✓ Non-insulin antidiabetics (e.g., metformin, glipizide, pioglitazone)
- ✓ Renin-angiotensin-system (RAS) antagonists (e.g., ACE inhibitors-lisinopril, benazepril; ARBs-losartan, valsartan)

Thank you for taking notice when your office receives these faxes from MedImpact and your timely review and response to make the switch to a 90-day supply, as you deem clinically appropriate.

We appreciate your partnership in serving IEHP Members and improving health outcomes.

Sincerely,

IEHP Pharmaceutical Services